Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia.

Authors:

Abstract
9518 Background: Alopecia is an emotionally traumatic side effect for breast cancer (BC) patients (pts) undergoing adjuvant chemotherapy (CTX). The DigniCap System is the first scalp cooling system studied under a clinical trial approved by the Food and Drug Administration (FDA) to minimize alopecia. Methods: This prospective trial evaluated the clinical performance of the DigniCap System in women with early stage BC receiving adjuvant CTX. The primary endpoint was efficacy evaluated by pt self-assessment of 5 photographs of the head using the Dean scale to estimate hair loss one month after the end of chemotherapy. A score of 0-2 ( ≤ 50% hair loss) was defined as treatment success. Tolerability was defined as the percentage of patients who completed all planned CTX cycles using the DigniCap System and by the Patient Symptoms Survey. Eligibility included women with stage I/II BC scheduled to receive adjuvant CTX, excluding sequential anthracycline/taxane regimens. With 100 pts enrolled, there was 90% powe...